Intranasal Fluticasone Propionate
The intranasal corticosteroid fluticasone propionate is an effective agent for the treatment of rhinitis, demonstrating potent local anti-inflammatory activity and little, if any, systemic activity. Intranasal fluticasone propionate has shown clinical efficacy similar to that of other intranasal corticosteroids, including beclomethasone (administered at up to a 2- fold higher dosage than fluticasone), budesonide, flunisolide and triamcinolone acetonide, and provides greater relief from nasal symptoms (including nasal blockage) than antihistamine agents and intranasal sodium cromoglycate. Its efficacy in the treatment of seasonal allergic rhinitis and perennial allergic and nonallergic rhinitis has been demonstrated in large well-controlled studies in which the drug maintained adequate control of symptoms when administered in a once daily dose of 200µg. In addition, fluticasone propionate has shown similar efficacy to that of beclomethasone in the treatment of nasal polyps; however, its use in the postoperative setting requires further investigation.
Intranasal fluticasone propionate is well tolerated in the majority of patients, the incidence of adverse events being similar to that seen with placebo. Pharmacoeconomic analyses indicate that intranasal fluticasone propionate is significantly more cost-effective than the antihistamines terfenadine and loratadine. Overall quality of life was improved to a similar extent by fluticasone propionate and beclomethasone.
In conclusion, recent clinical experience has confirmed that intranasal fluticasone propionate is a convenient, effective and well tolerated alternative to other intranasal corticosteroids and antihistamines for the treatment of rhinitis when administered once daily.
Fluticasone propionate has a 3- and 1.5-fold higher affinity for the glucocorticoid receptor than budesonide and the active metabolite of beclomethasone, respectively. The anti-inflammatory activity of intranasal fluticasone propionate has been demonstrated in nasal allergen provocation tests in patients with allergic rhinitis and also in skin vasoconstriction assays, in which the potency of fluticasone propionate was at least twice that of beclomethasone and was similar to or up to 3-fold greater than that of budesonide. Fluticasone propionate reduced both the early and late responses to allergen challenge, as evidenced by reductions in the levels of inflammatory cells and mediators in nasal lavage fluid. In addition, the nasal inspiratory peak flow from 0 to 24 hours after allergen challenge was significantly improved with fluticasone propionate compared with placebo. Fluticasone propionate was more effective in improving total nasal airflow than the antihistamines terfenadine, astemizole and loratadine.
Treatment with intranasal fluticasone propionate reduced the number of eosinophils and basophils in nasal lavage fluid in patients with rhinitis, but had no effect on the levels of neutrophils, goblet cells or epithelial cells.
With regard to the hypothalamic-pituitary-adrenal (HPA) axis, well designed clinical trials have shown fluticasone to have no effect on plasma or urinary cortisol levels in patients with rhinitis.
Little is known about the pharmacokinetic properties of intranasal fluticasone propionate, as plasma concentrations are generally below the limit of detection after administration by this route (<50 ng/L). The amount of fluticasone propionate present in the systemic circulation after intranasal administration has been estimated to be <2% of the dose. As oral bioavailability is negligible (<1%), it is likely that the small systemic exposure observed after intranasal administration results from absorption of the drug through the nasal mucosa.
Studies in healthy male volunteers using intravenous and oral formulations of fluticasone propionate reported the drug to have a rapid plasma clearance rate (1.11 L/min), similar to that of hepatic blood flow. The mean volume of distribution at steady-state was 318L. Low plasma concentrations of fluticasone propionate following oral administration may be attributed to the fact that the drug is poorly absorbed and is subject to extensive hepatic metabolism. Most oral flutica-sone propionate is eliminated in the faeces; the elimination half-life after intravenous administration is about 8 hours.
Large, well designed multicentre clinical trials have shown intranasal fluticasone propionate to be an effective agent for the treatment of seasonal allergic rhinitis in adults, adolescents and children. The drug significantly improved nasal symptoms (including sneezing, itching, nasal blockage and rhinorrhoea), increased the number of symptom-free days and reduced the use of rescue medication compared with placebo. The efficacy of fluticasone propionate in improving nasal symptoms was similar in adults given a dosage of 100µg twice daily or 200µg once daily; however, some studies observed that the use of rescue medication was lower in patients given the 100µg twice daily dosage. Studies in adults with severe symptoms indicate that administration of a higher dosage of fluticasone propionate (200µg twice daily) may be advantageous compared with a once daily 200µg dosage. Once daily dosages of fluticasone propionate 100 or 200µg showed similar efficacy in improving symptoms in children.
In comparisons with other intranasal corticosteroids, fluticasone propionate 200 µg/day improved nasal symptoms to a similar extent to beclomethasone 336 to 400 jug/day, flunisolide 200 µg/day and triamcinolone acetonide 220 fig/day. Fluticasone propionate 200µg once daily showed similar efficacy to budesonide 128 µg/day but appeared less effective than budesonide 250 jug/day in reducing sneezing in one study. All other nasal symptom scores were improved to a similar extent. The oral antihistamines astemizole 10 mg/day, cetirizine 10 mg/day, loratadine 10 mg/day and terfenadine 120 mg/day were all less effective than fluticasone propionate in relieving nasal symptoms in patients with seasonal allergic rhinitis.
Fluticasone propionate 200µg administered once daily starting before and continuing throughout the pollen season reduced the incidence of nasal symptoms of seasonal allergic rhinitis. Fluticasone propionate prophylaxis was superior to sodium cromoglycate, and combined treatment with cetirizine did not offer any advantages over fluticasone propionate monotherapy in preventing the onset of nasal symptoms.
Intranasal fluticasone propionate was an effective agent for the treatment of perennial allergic and nonallergic rhinitis in adults, adolescents and children. Nasal symptoms were significantly improved in adults treated with fluticasone propionate (100µg twice daily or 200µg once daily) compared with placebo and the drug was as effective as intranasal beclomethasone in large double-blind studies. One study found that during prolonged therapy of up to a year, improvements in nasal blockage and discharge were significantly greater in patients with perennial allergic rhinitis treated with fluticasone propionate 200µg twice daily than in those treated with the same dosage of beclomethasone. Fluticasone propionate 100µg once or twice daily was as effective as beclomethasone 200µg twice daily in the treatment of symptoms in children with either perennial allergic or nonallergic rhinitis.
Fluticasone propionate has shown similar efficacy to beclomethasone in improving symptoms associated with the presence of nasal polyps. It has also shown efficacy in the postoperative setting in preventing the recurrence of nasal polyps following surgery; however, preliminary findings from a small nonblinded study, showing fluticasone to be associated with an increased risk of infection after surgery compared with beclomethasone (when used as an adjuvant to prevent nasal polyp recurrence), require further investigation.
Intranasal fluticasone propionate was well tolerated in both adults and children when administered for periods of up to 12 months in large well-controlled clinical trials. Apart from intranasal bleeding, the tolerability profile of fluticasone propionate did not differ significantly from that of placebo and, in double-blind comparative trials, fluticasone propionate was as well tolerated as intranasal beclomethasone and budesonide and the antihistamines terfenadine and lorata-dine. Adverse events were generally mild to moderate, the most common being epistaxis/blood in the nasal mucus, nasal burning, nasal dryness, sore throat and headache. The drug does not suppress adrenal function and has not been associated with oropharyngeal candidiasis or nasal septal perforation. Preliminary findings indicate that long term treatment with fluticasone propionate (up to 1 year) does not cause ocular or bone changes.
Pharmacoeconomic and Quality-of-Life Considerations
Pharmacoeconomic analysis found fluticasone propionate to be more cost-effective in the treatment of seasonal allergic rhinitis than the antihistamines terfenadine and loratadine (cost-effectiveness ratios 1: 2.5 and 1: 5.7 for fluticasone propionate versus terfenadine and loratadine, respectively). In another study, fluticasone propionate treatment was associated with a lower cost per unit of efficacy than terfenadine. Studies have shown that overall quality of life was similar during fluticasone propionate and beclomethasone treatment, whereas fluticasone propionate was more effective than astemizole in improving quality-of-life parameters.
Dosage and Administration
The recommended dosage of intranasal fluticasone propionate for the prophylaxis and treatment of nasal symptoms in adults and adolescents (>12 years) with seasonal allergic rhinitis or perennial allergic or nonallergic rhinitis is 200µg once daily. For the treatment of nasal symptoms in children (≥4 years) with seasonal or perennial allergic rhinitis, the recommended dosage is 100µg once daily. Additional therapy to control eye symptoms may be required.
Unable to display preview. Download preview PDF.
- 6.Viegas M, Gomez E, Brooks J, et al. Effect of the pollen season on nasal mast cells. BMJ 1987; 296: 1572–3Google Scholar
- 8.Feather I, Wilson S, Smith S, et al. The accumulation of mast cells and eosinophils in the nasal mucosa in seasonal allergic rhinitics during natural pollen exposure, is inhibited by prophylactic fluticasone propionate aqueous nasal spray [abstract]. Am Rev Respir Dis 1992 Apr; 145: A853Google Scholar
- 9.Feather I, Wilson S, Smith S, et al. Prophylactic fluticasone propionate aqueous nasal spray inhibits the accumulation of mucosal eosinophils and mast cells in seasonal allergic rhinitis [abstract]. Allergy 1992; 47(12) Suppl.: 249Google Scholar
- 11.Holmberg K, Juliusson S, Karlsson G, et al. Effects of 4 weeks treatment with the topical glucocorticoid fluticasone on allergen-induced symptoms, tissue mast cells and histamine in the nasal mucosa [abstract]. XIV International Congress of Allergology and Clinical Immunology; 1991 Oct 13–18; Kyoto, 183Google Scholar
- 12.Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994 Oct; 24: 930–9PubMedCrossRefGoogle Scholar
- 13.Jacobson MR, Rak S, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid on allergen-induced cellular infiltration in the nasal mucosa [abstract]. Clin Exp Allergy 1994 Feb; 24: 183Google Scholar
- 20.Godthelp T, Holm AF, Blom HM, et al. A double-blind comparison of two different dosages of fluticasone propionate aqueous nasal spray in the treatment of patients with allergic perennial rhinitis - a biopsy study. Allergologie 1996; 19: 42Google Scholar
- 22.Masuyama K, Rak S, Jacobson MR, et al. Rhinitis at the cellular level. Eur Resp Rev 1994; 4: 252–5Google Scholar
- 26.Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200µg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98: 274–82PubMedCrossRefGoogle Scholar
- 36.Andersson N, Klint S, Randwall G, et al. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay [abstract]. Thorax 1994; 149: 422PGoogle Scholar
- 37.English AF, Neate MS, Quint DJ, et al. Some biological activities of a new corticosteroid, fluticasone propionate [abstract]. Br J Pharmacol 1994 Jul; 112 Suppl: 591PGoogle Scholar
- 38.Ransom J, Rogenes P, Field E, et al. Fluticasone propionate aqueous nasal spray increases mean total nasal airflow compared with astemizole or terfenadine [abstract]. In: 1994 Annual Meeting — American College of Allergy and Immunology; 1994: 55Google Scholar
- 41.Prenner BM. Hypothalamic-pituitary-adrenal axis suppression during inhaled or intranasal corticosteroid treatment. Adv Ther 1996; 13: 154–60Google Scholar
- 44.Ventresca GP, Mackie AE, Moss JA, et al. Absorption of oral fluticasone propionate in healthy subjects [abstract]. Am J Respir Crit Care Med 1994 Apr; 149 (Pt2): 214Google Scholar
- 45.Falcoz C, Mackie AE, McDowall J, et al. Oral bioavailability of fluticasone propionate in healthy subjects [abstract]. Br J Clin Pharmacol 1996 May; 41: 459P–60PGoogle Scholar
- 48.McDowall JE, Mackie AE, Bye A, et al. Very low systemic exposure to intranasal fluticasone propionate [abstract]. J Allergy Clin Immunol 1995; 95 (Pt 2): 194Google Scholar
- 51.Hampel F, Howland W, Martin B, et al. The efficacy of fluticasone propionate aqueous nasal spray for treatment of rhinitis is dependent on topical application [abstract]. J Allergy Clin Immunol 1994 Jan; 93: 165,Pt2Google Scholar
- 60.Lund V, Stokes I, Davies B, et al. A placebo-controlled study of fluticasone propionate and beclomethasone dipropionate in seasonal rhinitis. Clin Exp Allergy 1990; 20 Suppl. 1: 102Google Scholar
- 61.Malmberg H, Holopainen E. Fluticasone propionate once daily in patients with seasonal rhinitis: a European multi-centre study. Clin Exp Allergy 1990; 29 Suppl. 1: 102Google Scholar
- 63.Stern MA, Harris P, Dahl R, et al. A placebo controlled study comparing budesonide 256µg and 128µg with fluticasone propionate 200µg in patients with seasonal allergic rhinitis [abstract]. Eur Respir J 1994; 7 Suppl. 18: 31sGoogle Scholar
- 64.Johannessen TA. A comparison of fluticasone propionate, flunisolide and placebo in patients with seasonal allergic rhinitis to birch pollen — a multicentre trial. Clin Exp Allergy 1990; 20 Suppl. 1: 102Google Scholar
- 66.Belling U. Once daily treatment with fluticasone propionate aqueous nasal spray or astemizole tablets for seasonal rhinitis [abstract]. Clin Exp Allergy 1990; 20 Suppl. 1: 98Google Scholar
- 67.Lemanske R, Dunn K, Galant S, et al. Fluticasone propionate aqueous nasal spray is more effective than astemizole in the treatment of seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1994 Jan; 93 (Pt2): 165Google Scholar
- 68.Stricker WE, Klimas JT, Mendelson L, et al. Intranasal fluticasone propionate is more effective than astemizole for seasonal allergic rhinitis [abstract]. Ann Allergy 1994 Jan; 72: 86Google Scholar
- 69.Vervloet D, Desfougères J-L, Charpin D. Fluticasone propionate aqueous nasal spray versus cetirizine in seasonal rhinitis [abstract]. J Allergy Clin Immunol 1992 Jan; 89: 304Google Scholar
- 70.Cook C, Wisniewski M, Cox F, et al. Intranasal fluticasone propionate (FP) is more effective than loratadine (LOR) for the treatment of seasonal allergic rhinitis [abstract]. Allergy 1996; 51 Suppl. 31: 152Google Scholar
- 71.Géhanno P, Desfourgères JL. Fluticasone propionate aqueous nasal spray once daily versus loratadine once daily in the treatment of seasonal allergic rhinitis [abstract]. Eur Respir J 1993; 6 (Suppl. 17): 603sGoogle Scholar
- 74.Shulan D, Reed KD, Anschuetz G, et al. Intranasal fluticasone propionate (Fp) compared with loratadine (LOR) in the 1995 spring tree season [abstract]. Ann Allergy Asthma Immunol 1996 Jan; 76: 96Google Scholar
- 77.Stern MA, Benincasa C. Once daily fluticasone propionate aqueous nasal spray prophylaxis for seasonal allergic rhinitis: is time of dosing important? [abstract]. Allergy 1993; 48 Suppl. 16: 86Google Scholar
- 78.Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy 1993 Jul; 48: 327–33PubMedCrossRefGoogle Scholar
- 80.Hebert J, Drouin M, Yang WH, et al. Once-a-day intranasal fluticasone propionate is effective for patients with perennial allergic rhinitis [abstract]. J Allergy Clin Immunol 1995 Jan; 95: 197,Pt2Google Scholar
- 85.Seiner J, Banov C, Boltansky H, et al. Fluticasone propionate aqueous nasal spray effectively treats perennial non-allergic rhinitis [abstract]. J Allergy Clin Immunol 1994 Jan; 93 (Pt 2): 165Google Scholar
- 86.Scadding GK, Lund VJ, Holmstrom M, et al. Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinol 1991; 11 Suppl.: 37–43Google Scholar
- 87.Ngamphaiboon J, Thepchatri A, Chatchatee P. A double-blind comparison of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis in children [abstract]. Allergy 1995; 50 Suppl. 26: 67Google Scholar
- 88.Baba S, Matsunaga T, Saito H, et al. Clinical studies of fluticasone propionate aerosol (5th report). Study on paediatric nasal allergy [in Japanese]. Jibi to Rinsho 1992; 38 Suppl. 1: 367–83Google Scholar
- 89.Holmberg K, Karlsson G. Nasal polyps: Surgery or pharmacological intervention? Eur Respir Rev 1994; 4(20): 260–5Google Scholar
- 91.Lund VJ, Dorman J, Sykes AP, et al. Acoustic rhinometry in the assessment of intranasal steroid therapy for nasal polyposis [abstract]. EAACI; 1996 Jun 2–5; Budapest, HungaryGoogle Scholar
- 93.Rowe-Jones JM, Mackay IS. Infection following functional endoscopic sinus surgery with post-operative topical nasal steroids. J Allergy Clin Immunol 1997; 99: S4Google Scholar
- 96.Holm AF, Godthelp T, Vroom TM, et al. Safety and efficacy of one-year treatment with fluticasone propionate on clinical signs and inflammatory cells in the nasal mucosa of allergic perennial rhinitis patients. Allergologie 1996; 19: 43Google Scholar
- 97.Li J, Lyles K, Halstenson C, et al. Long-term safety study of fluticasone propionate aqueous nasal spray [abstract]. In: 1994 Annual Meeting American College of Allergy and Immunology. 1994 Nov 5-9: 9Google Scholar
- 100.US Department of Health and Human Services NIH. Report of the NIAID task force on immunology and allergy. National Institutes of Health (NIH) 1990; 91–2414, Betheseda (MD)Google Scholar
- 103.Berka C, Chin W. Fluticasone propionate intranasal steroid: cost-effectiveness vs. antihistamines [abstract]. J Allergy Clin Immunol 1994 Jan; 93: 165Google Scholar
- 105.Mackowiak JI. Fluticasone propionate aqueous nasal spray (FP) improves rhinitis quality of life and reduces lost labor costs [abstract]. Ann Allergy 1994 Jan; 72: 99Google Scholar
- 111.Busse WW. Role of antihistamines in allergic disease. Ann Allergy 1994; 71: 371–5Google Scholar
- 113.Bernstein JM, Lee J, Conboy K, et al. Further observations of the role of IgE mediated hypersensitivity in recurrent otitis media with effusion. Head Neck Surg 1985; 93: 611–5Google Scholar
- 114.Scadding GK. The pathogenesis of otitis media with effusion, allergy revisited. J Audiolog Med 1995; 4: 173–81Google Scholar